Low-Fluence Q-Switched Neodymium-Doped Yttrium Aluminum Garnet Laser for Melasma with Pre- or Post-Treatment Triple Combination Cream
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Se-Yeong | - |
dc.contributor.author | Shin, Jae-Bin | - |
dc.contributor.author | Yeo, Un-Cheol | - |
dc.contributor.author | Kim, Won-Serk | - |
dc.contributor.author | Kim, Il-Hwan | - |
dc.date.accessioned | 2021-09-08T02:36:23Z | - |
dc.date.available | 2021-09-08T02:36:23Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2010-06 | - |
dc.identifier.issn | 1076-0512 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/116293 | - |
dc.description.abstract | BACKGROUND Topical triple combination (TC) treatment is considered the primary approach to melasma. Recently, collimated low-fluence 1,064-nm Q-switched neodymium-doped yttrium aluminum garnet (Nd: YAG) laser treatment has attracted attention as an alternative approach. OBJECTIVES To compare the clinical efficacy and adverse effects of low-fluence Q-switched Nd: YAG laser when performed before and after treatment with topical TC using a split-face crossover design. METHODS Thirteen patients with melasma received topical treatment with TC cream or 1,064-nm Q-switched Nd: YAG laser treatment on opposite sides of the face for 8 weeks, and then treatments were reversed for 8 weeks. Responses were evaluated using the Melasma Area and Severity Index scoring system, spectrophotometry measurements, and a subjective self-assessment method. RESULTS After 16 weeks, better results were seen in subjective assessments when laser treatment was used after 8 weeks of topical TC treatment than before usage of TC. There were no significant adverse effects with the laser treatments. CONCLUSIONS Laser treatment after topical TC cream was found to be safer and more effective than the post-treatment use of topical agents. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject | FLUOCINOLONE ACETONIDE 0.01-PERCENT | - |
dc.subject | GLYCOLIC ACID PEELS | - |
dc.subject | HYDROQUINONE 4-PERCENT | - |
dc.subject | TRETINOIN 0.05-PERCENT | - |
dc.subject | EFFICACY | - |
dc.subject | SAFETY | - |
dc.subject | PHOTOTHERMOLYSIS | - |
dc.subject | TRIAL | - |
dc.subject | SKIN | - |
dc.title | Low-Fluence Q-Switched Neodymium-Doped Yttrium Aluminum Garnet Laser for Melasma with Pre- or Post-Treatment Triple Combination Cream | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Il-Hwan | - |
dc.identifier.doi | 10.1111/j.1524-4725.2010.01523.x | - |
dc.identifier.scopusid | 2-s2.0-77952961823 | - |
dc.identifier.wosid | 000277980300011 | - |
dc.identifier.bibliographicCitation | DERMATOLOGIC SURGERY, v.36, no.6, pp.909 - 918 | - |
dc.relation.isPartOf | DERMATOLOGIC SURGERY | - |
dc.citation.title | DERMATOLOGIC SURGERY | - |
dc.citation.volume | 36 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 909 | - |
dc.citation.endPage | 918 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.subject.keywordPlus | FLUOCINOLONE ACETONIDE 0.01-PERCENT | - |
dc.subject.keywordPlus | GLYCOLIC ACID PEELS | - |
dc.subject.keywordPlus | HYDROQUINONE 4-PERCENT | - |
dc.subject.keywordPlus | TRETINOIN 0.05-PERCENT | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | PHOTOTHERMOLYSIS | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | SKIN | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.